Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk

Liver International

Volumn 34, Issue 5, 2014, Pages 728-736

  Han, Yifang ^a   Pu, Rui ^a   Han, Xue ^b   Zhao, Jun ^a   Li, Weiping ^c   Yin, Jianhua ^a   Zhang, Yuwei ^a   Shen, Qiuxia ^a   Xie, Jiaxin ^a   Zhang, Qi ^a   Jiang, Shuang ^c   Li, Juhong ^c   Zhang, Hongwei ^a   Wang, Hongyang ^a   Cao, Guangwen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Yangpu District   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; MiR 218; Mutation; Polymorphysims

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MICRORNA; MICRORNA 218; UNCLASSIFIED DRUG; MIRN218 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENHANCER REGION; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMOTER REGION; QUANTITATIVE ANALYSIS; SEROCONVERSION; START CODON; VIRUS MUTATION; AGED; CASE CONTROL STUDY; COMPLICATION; GENETICS; HEPATITIS B; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; MUTATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY; VIRUS GENE; VIRUS REPLICATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENES, VIRAL; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; VIRUS REPLICATION;

EID: 84897956748     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12313     Document Type: Article

References (48)

1. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol 2011; 26: 221-7.
2. Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011; 29: 3643-50.
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
4. Yin J, Zhang H, He Y, et al. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 2010; 19: 777-86.
5. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
6. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
7. Zhu Y, Jin Y, Guo X, et al. Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2623-30.
8. Yuen MF, Tanaka Y, Shinkai N, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57: 98-102.
9. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101: 1066-82.
10. Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007; 27: 1356-63.
11. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-43.
12. Yuan JM, Ambinder A, Fan Y, et al. Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2009; 18: 590-4.
13. Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 2011;141:1412-21, 1421.e1-5.
14. Mun HS, Lee SA, Kim H, et al. Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol 2011; 85: 123-32.
15. Chen L, Zhang Q, Chang W, et al. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012; 48: 1977-87.
16. Jiang DK, Sun J, Cao G, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 2013; 45: 72-5.
17. He Y, Zhang H, Yin J, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis 2009; 30: 1916-22.
18. Zhang Q, Pu R, Du Y, et al. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets. Cancer Lett 2012; 321: 1-12.
19. Necela BM, Carr JM, Asmann YW, Thompson EA. Differential expression of microRNAs in tumors from chronically inflamed or genetic [APC(Min/+)] models of colon cancer. PLoS One 2011; 6: e18501.
20. Song L, Huang Q, Chen K, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-β. Biochem Biophys Res Commun 2010; 402: 135-40.
21. Gao C, Zhang Z, Liu W, et al. Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer 2010; 116: 41-9.
22. Alajez NM, Lenarduzzi M, Ito E, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011; 71: 2381-91.
23. Martinez I, Gardiner AS, Board KF, et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008; 27: 2575-82.
24. Liu Y, Yan W, Zhang W, et al. MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep 2012; 28: 1013-21.
25. Li Q, Zhu F, Chen P. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun 2012; 424: 28-33.
26. Uesugi A, Kozaki K, Tsuruta T, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011; 71: 5765-78.
27. Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 2010; 70: 10392-401.
28. White NM, Bao TT, Grigull J, et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011; 186: 1077-83.
29. Jacquemin P, Lannoy VJ, Rousseau GG, Lemaigre FP. OC-2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor-6. J Biol Chem 1999; 274: 2665-71.
30. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 1983.e1-11.
31. Zhang LS, Liang WB, Gao LB, et al. Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol 2012; 31: 761-5.
32. Yin J, Xie J, Liu S, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 81-92.
33. Zhang HW, Yin JH, Li YT, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai China. Gut 2008; 57: 1713-20.
34. Yin J, Xie J, Zhang H, et al. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol 2010; 45: 1063-71.
35. Chen J, Yin J, Tan X, et al. Improved multiplex-PCR to identify hepatitis B virus genotypes A-F and subgenotypes B1, B2, C1 and C2. J Clin Virol 2007; 38: 238-43.
36. Xie J, Zhang Y, Zhang Q, et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with HBV mutations in hepatocellular carcinoma. Hepatology 2013; 57: 2369-77.
37. Kao JH, Liu CJ, Jow GM, et al. Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. Liver Int 2012; 32: 1373-81.
38. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15: 5761-9.
39. Chen BF, Liu CJ, Jow GM, et al. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-68.
40. Tsai HW, Lin YJ, Lin PW, et al. A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. Cancer 2011; 117: 2951-60.
41. Yin JH, Zhao J, Zhang HW, et al. HBV genotype C is independently associated with cirrhosis in community-based population. World J Gastroenterol 2010; 16: 379-83.
42. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-9.
43. Chen CH, Lee CM, Hung CH, et al. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int 2007; 27: 806-15.
44. Zhou X, Chen X, Hu L, et al. Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women. Gynecol Oncol 2010; 117: 287-90.
45. Yin J, Zhang H, Li C, et al. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 2008; 29: 1685-91.
46. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-72.
47. Li S, Qian J, Yang Y, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012; 8: e1002791.
48. Clifford RJ, Zhang J, Meerzaman DM, et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 2010; 52: 2034-43.